The 50-patient, single-arm trial studied the combination of tomuzotuximab and Daiichi Sankyo’s gatipotuzumab. Credits: Yale Rosen.

Glycotope’s tomuzotuximab in epidermal growth factor receptor (EGFR) expressing solid tumours saw its Phase Transition Success Rate (PTSR) drop five points to 63%. The update occurred on 11 June on the heels of Phase Ib data reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually on 4–8 June. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.

The Berlin, Germany-based company updated Phase Ib GATTO trial’s secondary endpoint data, showing patients who received tomuzotuximab had a median progression free survival (PFS) of 1.9 months and a 3.8-month duration of response (abstract no 2522). The 50-patient, single-arm trial studied the combination of tomuzotuximab and Daiichi Sankyo’s gatipotuzumab.

Despite the PTSR change, the data did not result in any change to the drug’s Likelihood of Approval (LoA), which remained at 7%. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm and is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

William Newton is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.